The majority of hypercalcemia cases are due to which etiologies?

The majority of hypercalcemia cases are due to which etiologies?

• A. Vitamin D intoxication
• B. Renal failure
• C. Hyperthyroidism
• D. Primary hyperparathyroidism or malignancy

Answer: (D)

Hypercalcemia is most often caused by conditions that directly raise calcium through the parathyroid axis or through cancer-related mechanisms. The two biggest culprits are primary hyperparathyroidism and malignancy. In primary hyperparathyroidism, usually due to a parathyroid adenoma, PTH remains inappropriately elevated. This drives calcium upward by increasing bone resorption, enhancing renal calcium reabsorption, and boosting intestinal calcium absorption via activation of vitamin D. That combination reliably produces sustained hypercalcemia. Malignancy raises calcium through two main pathways. One is humoral hypercalcemia of malignancy, where tumors secrete PTH-related peptide (PTHrP) that mimics PTH and raises calcium. The other is osteolytic metastases, where cytokines and other mediators stimulate bone resorption directly. In both scenarios, calcium climbs, but PTH levels are typically suppressed because the high calcium feedback dampens PTH secretion. Other causes exist, such as vitamin D intoxication or renal disease, but they account for a smaller share of hypercalcemia cases. Vitamin D excess increases intestinal calcium absorption, while renal disease more often leads to abnormalities that lower calcium or produce secondary hyperparathyroidism rather than a majority of hypercalcemic presentations. So, the majority of hypercalcemia cases arise from primary hyperparathyroidism or malignancy-driven mechanisms.

Hypercalcemia is most often caused by conditions that directly raise calcium through the parathyroid axis or through cancer-related mechanisms. The two biggest culprits are primary hyperparathyroidism and malignancy.

In primary hyperparathyroidism, usually due to a parathyroid adenoma, PTH remains inappropriately elevated. This drives calcium upward by increasing bone resorption, enhancing renal calcium reabsorption, and boosting intestinal calcium absorption via activation of vitamin D. That combination reliably produces sustained hypercalcemia.

Malignancy raises calcium through two main pathways. One is humoral hypercalcemia of malignancy, where tumors secrete PTH-related peptide (PTHrP) that mimics PTH and raises calcium. The other is osteolytic metastases, where cytokines and other mediators stimulate bone resorption directly. In both scenarios, calcium climbs, but PTH levels are typically suppressed because the high calcium feedback dampens PTH secretion.

Other causes exist, such as vitamin D intoxication or renal disease, but they account for a smaller share of hypercalcemia cases. Vitamin D excess increases intestinal calcium absorption, while renal disease more often leads to abnormalities that lower calcium or produce secondary hyperparathyroidism rather than a majority of hypercalcemic presentations.

So, the majority of hypercalcemia cases arise from primary hyperparathyroidism or malignancy-driven mechanisms.